Janux Therapeutics reported revenue of $10.27M and net income of -$24.85M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 41.17M | 23.53M | 41.39M | 41.50M | 41.55M | 41.62M | 41.80M | 41.87M | 46.15M | 46.25M | 51.84M | 52.16M | 52.34M | 59.06M | 59.17M | 59.30M | 60.12M | 60.38M | 60.87M | 61.08M | |||||
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 1.16M | 1.62M | 1.59M | 2.37M | 1.81M | 2.85M | 2.05M | 1.06M | 2.52M | 2.46M | 1.25M | 8.90M | 0.44M | 10.00M | 3.73M | 10.27M | |||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 8.41M | 11.17M | 10.18M | 14.09M | 13.74M | 15.43M | 15.87M | 14.92M | 11.89M | 12.24M | 14.07M | 14.90M | 18.61M | 20.81M | 25.05M | 34.66M | 34.63M | 31.55M | 26.81M | 30.99M | |||||
| Selling, General & AdministrativeSG&A | 3.66M | 3.94M | 4.95M | 5.54M | 6.10M | 5.68M | 6.46M | 6.88M | 6.44M | 6.36M | 7.34M | 7.82M | 17.67M | 8.22M | 9.84M | 10.45M | 10.62M | 10.85M | 11.13M | 10.96M | |||||
| Operating ExpensesOpex | 12.06M | 15.11M | 15.13M | 19.63M | 19.84M | 21.11M | 22.33M | 21.80M | 18.33M | 18.60M | 21.41M | 22.72M | 36.28M | 29.02M | 34.90M | 45.12M | 45.25M | 42.40M | 37.95M | 41.96M | |||||
| Operating IncomeOp. Inc | -10.90M | -13.49M | -13.54M | -17.26M | -18.02M | -18.27M | -20.28M | -20.75M | -15.81M | -16.14M | -20.16M | -13.82M | -35.84M | -29.02M | -34.90M | -45.12M | -35.25M | -42.40M | -34.21M | -31.69M | |||||
| EBIT | -10.90M | -13.49M | -13.54M | -17.26M | -18.02M | -18.27M | -20.28M | -20.75M | -15.81M | -16.14M | -20.16M | -13.82M | -35.84M | -29.02M | -34.90M | -45.12M | -35.25M | -42.40M | -34.21M | -31.69M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Interest Expenses | |||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.14M | 0.07M | 0.13M | 0.37M | 1.33M | 2.20M | 2.82M | 3.24M | 4.25M | 4.38M | 5.40M | 7.86M | 7.78M | 8.81M | 11.39M | 11.26M | 10.94M | 10.46M | 9.85M | 9.72M | |||||
| Non Operating IncomeNon Op. Inc. | 0.14M | 0.07M | 0.13M | 0.37M | 1.33M | 2.20M | 2.82M | 3.24M | 4.25M | 4.38M | 5.40M | 7.86M | 7.78M | 8.81M | 11.39M | 11.26M | 10.94M | 10.46M | 9.85M | 9.72M | |||||
| Net income details | |||||||||||||||||||||||||
| EBT | -10.77M | -13.42M | -13.41M | -16.89M | -16.70M | -16.07M | -17.46M | -17.51M | -11.57M | -11.76M | -14.76M | -5.96M | -28.06M | -20.22M | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M | |||||
| Profit After TaxPAT | -10.77M | -13.69M | -14.98M | -17.23M | -17.07M | -15.32M | -17.46M | -17.83M | -11.68M | -11.76M | -15.95M | -7.05M | -28.06M | -20.22M | -23.51M | -33.87M | -24.31M | -31.95M | -28.10M | -24.85M | |||||
| Income from Continuing OperationsIncome (Continuing) | -10.77M | -13.42M | -13.41M | -16.89M | -16.70M | -16.07M | -17.46M | -17.51M | -11.57M | -11.76M | -14.76M | -5.96M | -28.06M | -20.22M | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M | |||||
| Consolidated Net IncomeConsol Net Inc. | -10.77M | -13.42M | -13.41M | -16.89M | -16.70M | -16.07M | -17.46M | -17.51M | -11.57M | -11.76M | -14.76M | -5.96M | -28.06M | -20.22M | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M | |||||
| Income towards Parent CompanyParent Net Inc | -10.77M | -13.42M | -13.41M | -16.89M | -16.70M | -16.07M | -17.46M | -17.51M | -11.57M | -11.76M | -14.76M | -5.96M | -28.06M | -20.22M | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M | |||||
| Net Income towards Common StockholdersNet Income | -10.77M | -13.42M | -13.41M | -16.89M | -16.70M | -16.07M | -17.46M | -17.51M | -11.57M | -11.76M | -14.76M | -5.96M | -28.06M | -20.22M | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.26 | -0.57 | -0.32 | -0.41 | -0.40 | -0.39 | -0.42 | -0.42 | -0.25 | -0.27 | -0.30 | -0.11 | -0.51 | -0.38 | -0.38 | -0.55 | -0.39 | -0.52 | -0.39 | -0.35 | |||||
| EPS (Diluted) | -0.26 | -0.57 | -0.32 | -0.41 | -0.40 | -0.39 | -0.42 | -0.42 | -0.25 | -0.27 | -0.30 | -0.11 | -0.51 | -0.38 | -0.38 | -0.55 | -0.39 | -0.52 | -0.39 | -0.35 | |||||
| Shares Outstanding | 41.13M | 23.53M | 41.32M | 41.45M | 41.53M | 41.47M | 41.76M | 41.84M | 45.71M | 44.02M | 49.05M | 54.45M | 54.63M | 53.75M | 61.79M | 61.90M | 62.02M | 61.97M | 62.67M | 62.94M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 41.13M | 23.53M | 41.32M | 41.45M | 41.53M | 41.47M | 41.76M | 41.84M | 45.71M | 44.02M | 49.05M | 54.45M | 54.63M | 53.75M | 61.79M | 61.90M | 62.02M | 61.97M | 62.67M | 62.94M | |||||
| EBITDA | -10.90M | -13.49M | -13.54M | -17.26M | -18.02M | -18.27M | -20.28M | -20.75M | -15.81M | -16.14M | -20.16M | -13.82M | -35.84M | -29.02M | -34.90M | -45.12M | -35.25M | -42.40M | -34.21M | -31.69M | |||||
| Interest ExpensesInt Expense |